Vision

We believe that Delivery is the key to success of the RNAi therapeutic field.

As a provider of delivery technologies to RNAi therapeutic companies, we hope that each successful delivery platform developed by Traversa will have outstanding potential in the form of field licensing opportunities across multiple acute, chronic and infectious human diseases.  As we deepen our pipeline, we look forward to developing more advanced systemic delivery solutions, as well as cell-targeted direct delivery systems providing the next generation of specificity and safety.  

Forward Looking Statements

Any statements in this website that are not historical facts are forward-looking statements that involve risks and uncertainties; actual results may differ from the forward-looking statements. Sentences or phrases that use such words as "believes," "anticipates," "plans," "may," "hopes," "can," "will," "expects," "is designed to," "with the intent," "potential" and others indicate forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company undertakes no obligation to release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.